$600K+ investment leverages combination of FDA approved treatments to overcome drug resistance in EGFR-positive lung cancer WASHINGTON, Oct. 28, 2026 /PRNewswire/ -- A groundbreaking clinical trial aimed at overcoming drug resistance in EGFR-positive non-small cell lung cancer (NSCLC),...